Navigation Links
AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
Date:8/12/2008

QUEBEC CITY, Aug. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrinology and oncology, announced today the appointment of Prof. Jurgen Engel, Ph.D. as its new President and CEO, effective as of September 1, 2008. Prof. Engel is currently Executive Vice President and Chief Scientific Officer of AEterna Zentaris. He succeeds Juergen Ernst, who had been acting as Interim President and CEO since April 2008. Mr. Ernst, current Chairman at AEterna Zentaris, will become Executive Chairman as of September 1, 2008.

"As a seasoned executive for many years at AEterna Zentaris, Prof. Engel has gained a deep knowledge of the Company's activities at all levels. We feel that his extensive expertise in drug development and commercialization as well as in strategic partnerships, make him the ideal person to lead the Company," said Mr. Ernst.

Prof. Engel added, "I am thrilled with this new challenge and will continue to dedicate all efforts to the successful development of our deep pipeline, especially the ongoing pivotal Phase 3 program in benign prostatic hyperplasia with our lead compound, cetrorelix."

Prof. Engel has been Chief Executive Officer of Zentaris AG since the beginning of 2001. Before joining AEterna Zentaris in December 2002, he was in charge of all R&D activities at ASTA Medica AG where he supervised more than 700 scientists and clinical professionals.

Prof. Engel holds a doctorate degree in organic chemistry from the Technical University of Braunschweig and an academic degree in pharmaceutical science from the University of Regensburg where he is an adjunct full professor at its School of Pharmacy. He is also Honorary Professor at
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
2. AEterna Zentaris Sells Quebec City Building for $7.1 million
3. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
4. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
5. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
6. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
7. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
8. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Announces Changes to its Management Team
11. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... (PRWEB) November 25, 2014 SonaCare ... Focused Ultrasound (HIFU) devices, recently participated in the ... Renal Mass 360° .” Key opinion leaders in ... advances related to small renal masses while attendees ... different ablative technologies in hands-on labs. Attendees at ...
(Date:11/26/2014)... OH (PRWEB) November 25, 2014 Miles ... has joined the Graphel Carbon Products team as Sales/Marketing ... sales, marketing, and customer service for the graphite industry. ... Miles to our team,” stated Dave Trinkley, VP of ... “His wide range of experience in the graphite industry, ...
(Date:11/26/2014)... 25, 2014 Bio-Techne Corporation (NASDAQ: ... Robert Gavin to serve in a newly created ... Division.  Mr. Gavin will be responsible for managing the ... the ProteinSimple business acquired in July 2014 and the ... Jose, California -based ProteinSimple develops and commercializes proprietary ...
(Date:11/24/2014)... Nov. 24, 2014  Last week, Representatives ... (D-NC) took a bold bipartisan step on ... the OPEN Act. Original co-sponsors of the legislation ... Act will incentivize drug makers and innovators to ... and pediatric cancers, which opens the door to ...
Breaking Biology Technology:SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... Signature pitchman, Billy Mays ENDORSES AND USES What Odor?® , ... Phoenix, ... to announce the launch of a massive marketing campaign for their flagship ... ,Nelson Grist, Founder and CEO of For The Earth Corp, anxiously awaits ...
... - BioMS Medical Corp (TSX: MS), a leading developer ... effective on March 16, 2009 the exercise term of ... holder to purchase one Class A common share at ... from March 23, 2009 to December 31, 2009. , ...
... invivodata, inc., ( http://www.invivodata.com ) the industry ... solutions and services for global clinical research, ... at upcoming international events to be delivered ... and regulatory consulting division, PRO Consulting(R) ( ...
Cached Biology Technology:Billy Mays Endorses New Odor Eliminating Product, What Odor? 2BioMS Medical warrant extension 2invivodata and PRO Consulting to Present at International Industry Events 2invivodata and PRO Consulting to Present at International Industry Events 3
(Date:11/6/2014)... occur because of metastasis, yet progress in preventing ... , "It,s been particularly challenging to design drugs ... fellow in systems biology at Harvard Medical School. ... after they,ve already metastasized." , Gujral and colleagues ... help researchers better understand how metastasis begins. Their ...
(Date:11/5/2014)... career to understanding the Earth,s climate and communicating ... deputy director and regional climatologist for the Western ... Redmond has more than three decades of experience ... data to the general public. , At its ... December 15-19, 2014 the American Geophysical Union (AGU) ...
(Date:11/4/2014)... PA) – Temple University School of Medicine announced ... winner, an initiative funded by the Bill & ... Professor of Obstetrics, Gynecology and Reproductive Sciences; and ... Temple University School of Medicine will pursue an ... "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... Université Laval biologist Connie Lovejoy has discovered new ... findings are reported in the January 12 edition ... discovered a new group of microscopic organisms, which ... extremely small size, measured in millionths of a ...
... to protect against human papillomavirus, has moved from scientific ... to make progress. While HPV vaccine efforts had the ... researchers are developing vaccines for cancers that are not ... system into attacking cancerous cells. Today at the ...
... from West Africa were cracking nuts with stone tools ... The result suggests chimpanzees developed this behaviour on their ... trait inherited from our common ancestor. Julio Mercader, Christophe ... site in Cote d'Ivoire, the only known prehistoric chimpanzee ...
Cached Biology News:Cancer vaccines -- Taking a jab at cancer by stimulating the immune system 2Cancer vaccines -- Taking a jab at cancer by stimulating the immune system 3Cancer vaccines -- Taking a jab at cancer by stimulating the immune system 4Cancer vaccines -- Taking a jab at cancer by stimulating the immune system 5The chimpanzee stone age 2
Human CCL26/Eotaxin-3 MAb (Clone 115002)...
Normal sheep serum collected from healthy normal sheep...
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
Pooled normal sreum with 0.1% sodium azide as preservative...
Biology Products: